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Abstract
Introduction: A research commentary published in 2005 pointed out that the apparently low
prevalence of Bipolar Disorder diagnosis as reported by epidemiological studies may be related to
the under-estimate of bipolar disorder cases generally yielded by methodological instruments that
are applied in such investigations.
New data apparently challenge this notion: More recent publications have presented new
results that apparently contradict the issues raised by the commentary, stating that the CIDI
interview, which is used in the most important epidemiological studies is not only valid but highly
reliable in identifying bipolar disorders.
Commentary: This paper analyzes the new data and concludes that they do not give a clear
indication as to how reliably the CIDI can recognize undiagnosed bipolar disorder cases. Further
research studies are needed on larger "negative" (to the CIDI) samples before the field will be
persuaded that CIDI really does what it is supposed to do.
Introduction
A research commentary published in 2005 [1] pointed out
that the apparently low prevalence of Bipolar Disorder
diagnosis as reported by epidemiological studies may be
related to the under-estimate of bipolar disorder cases
generally yielded by methodological instruments that are
applied in such investigations. The paper critically
addressed the issue of the clinician inferential-diagnostic
process, and concluded that the logical inference-process
for diagnosing manic episodes (in particular phases of
hypomania) in clinical settings was different from the one
performed in epidemiological studies, since, in clinical
practice, multiple different sources of information are
being relied on, whereas, in epidemiological surveys,
potentially insufficient and unreliable information is
being elicited merely from patients.
One consequence of the latter approach to psychiatric
diagnosis might be that a substantial percentage of indi-
viduals that have experienced manic, or more frequently,
hypomanic episodes, would be diagnostically mis-identi-
fied by non-expert interviewers. They are not able to con-
sider additional information such as elements gathered
from ad hoc questions, hints by patients, socio-cultural
and biographical backgrounds, and key external inform-
ants such as other patients, family members or friends.
The most likely cause is the low level of accuracy shown
by structured interviews administered by lay persons.
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surveys carried out in the community ("community sur-
veys") aiming to identify subjects who, on clinical exami-
nation, would be classified as having a mental disorder
and who are not receiving appropriate treatment, as their
disorder has not yet been recognized [2]. Such studies
must indicate the level of accessibility of psychiatric care
and thus are extremely relevant in terms of public health.
The diagnostic tools used must be: a) accurate against a
'gold standard' diagnostic tool and b) reliable. The diag-
nostic 'gold standard' must be the most accurate tool that
can determine if a subject may be considered as having the
disorder considered (in this case a bipolar disorder) in
terms of being suitable for treatment. In psychiatry, the
'gold standard' is the clinical diagnosis carried out in the
most reliable way according to standardized diagnostic
criteria, because only clinical diagnosis can decide if a sub-
ject is suitable for treatment.
The accuracy of a case finding tool (screening tool) is indi-
cated by 'sensitivity' [proportion of true cases (verified by
clinical diagnosis) identified as "positives"]; 'specificity'
[proportion of true non-cases (verfied by clinical diagno-
sis) identified as "negatives"]; 'predictive positive value'
[probability that a case identified by the test is a 'true pos-
itive'] and 'predictive negative value' [probability that a
non-case identified by the test is a 'true negative'].
Reliability may be measured in terms of K (Kappa), but
this measure is criticized for conditions with low fre-
quency (as is the case of bipolar disorders) because the
agreement in negatives may bias the measure [3]. For
example, if two clinicians evaluated 10 subjects and both
indicated one case, but it is not the same case, the agree-
ment in 8 negatives may weigh excessively in the calcula-
tion of K. The fact that a tool is reliable does not mean that
it is accurate.
In community surveys in mental health, two different
methods have been used: structured interviews (yes/no
answer with questions not modifiable by the interviewer)
administered by non-clinicians ("lay interviewers"); and
simple self-administered screening tools, which require a
second level test in which all "positives" and a proportion
of "negatives" must be evaluated clinically.
The issue of unreliability of structured interviews con-
ducted by non-specialists has been further elucidated by
findings from the clinical monitoring study that was car-
ried out along-side the ESEMED project, a European epi-
demiological investigation. The clinical monitoring study
reported a Kappa agreement coefficient (versus a clinical
interview) ranging from 0.23 in Spain to 0.49 in France
with regard to the diagnostic assessment of mood disor-
ders performed with the CIDI interview [4].
The above cited commentary paper underlined that if we
consider exactly what a Kappa of 0.4 implies for a disorder
with an "identified" prevalence rate of 2%, we discover
that the prevalence rate may have been under-estimated
approximately by 1.5-times. Therefore 67% of cases may
not have been identified, and 50% of identified cases may
be false positives. The work concluded that, "It is legiti-
mate to surmise that the prevalence reported by recent
(extremely costly) epidemiological surveys may be doubt-
ful".
New data apparently challenge this notion
A more recent publication presented new results that
apparently contradict the points made in the commen-
tary, [5] stating that the CIDI interview, which is used in
the most important epidemiological studies is not only
valid but highly reliable in identifying bipolar disorders.
The study compares the results of CIDI administered by
lay persons with the semi-structured interview SCID-IV
carried out by specialists. The results, while surprising,
seem irrefutable: out of 40 subjects, 10 of whom were
diagnosed as Bipolar I (by CIDI), 10 Bipolar II, 10 sub-
threshold BPD, and 10 with no disorder in the bipolar
spectrum, the concordance is almost perfect. The well-
known K coefficient is almost 1 for BP I, BP II and sub-
threshold cases. The article seems to have resolved the
debate, particularly since the authors included as collabo-
rators a number of excellent, well-respected clinicians,
some of whom had previously questioned CIDI applica-
bility.
But is the king still nude? [6]
We are not convinced of the conclusions of the article.
When there are suspicions that a case-detecting tool
under-estimates the frequency of an ailment, the most
serious problem is that of false negatives: affected individ-
uals who are not identified as such by the "case finding"
test.
As we pointed out, in the context of bipolar disorders, the
crucial diagnostic issue emerges with those individuals
who have experienced a hypomanic episode without
being aware of it, of the range of related morbidities and
co-morbidities, and of the negative outcomes of
"euphoric" or "irritable" periods that it caused.
If an instrument of "case finding" underestimates a disor-
der, the problem is not represented by those cases which
are identified as cases, In particular, as regards bipolar dis-
order, it is certain that a percentage of sufferers know that
they have had a manic episode, since they have received
treatment, and in the end have gained partial or complete
illness insight. Such cases would very likely be identified
through an instrument such as CIDI. However, the fact of
the matter is that not all subjects reach this level of aware-Page 2 of 4
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any case, an underestimate might arise from unidentified
individuals being somewhat different from those subjects
that are identified.
Let us hypothesize that the "real" rate of bipolar disorder
is not 2% as many epidemiological surveys have reported,
but reaches 4%, as suggested by some surveys conducted
using other methods [7]. This means that half of the cases
would not be recognized (false negatives).
In order to deny such a hypothesis we are interested to
know that the 2% of the cases "recognized" by the test are
the only ones. Their veracity can be further checked by a
clinical expert. Yet, this is not the only value: we need to
ensure the accuracy of the screening and the reliability of
frequency estimates reported by investigations with this
instrument. The crucial issue is to deny that there may
exist another 2% for that same definition, that is "differ-
ent" from the 2% identified.
We can refute this hypothesis if it can be demonstrated
that there are, on average, just two cases, two individuals
that have had a manic episode out of every 100 tested.
Let's look at how the test sample was defined. Thirty pos-
itive cases were selected, 10 each of BP I, BP II and sub-
threshold disorders, and 10 "BP negative". What would
the chance of recruiting a "false negative" among these 10
persons be if the true frequency in the general population
were 4%? If we accepted the hypothesis of a "true" preva-
lence of 4% and an "identified" prevalence of 2% (among
those identified by the surveys carried out applying the
CIDI) it would mean that 2% of people were false nega-
tive, and therefore the likelihood of finding at least one
false negative out of the 10 "negative" subjects recruited
for the validation study would be 2% of 10 individuals: P
= 0.20, whereas the probability of finding no false nega-
tive would very high (P = 0.80)
If one carefully analyzes the details of the study, it can be
observed that the concordance among the negatives was
1, that is, among these 10, none was affected (according
to both clinician assessment with SCID and lay-inter-
viewer evaluation with CIDI). It is likely that this was the
case and no false negatives were missed. Even if the prev-
alence was 4% and the CIDI test was not accurate, it
would be difficult to note such a fallacy in a small sample
that probably would not include any false negatives.
The authors claim to have weighted the sample to give a
good estimate of concordance. That is to say, from this
small sample of 10 true negatives with concordance of 1,
the estimate of concordance would be similar even with a
much larger sample such as 98% of the population.
Nevertheless, here is where the artifact originates: should
98 subjects be tested instead of 10, the CIDI might not
have been as accurate and the concordance would have
been lower, but with a "representative" sample of 10, it is
unlikely that any false negatives would have been encoun-
tered. Thus the weight of the sample is rather arbitrary,
particularly in terms of how closely it actually represented
the population which it is testing. In fact, the sample was
constructed in such a way as not to recognize undiagnosed
cases among the normal control population. This is para-
doxical for this is exactly what the main application of the
test should be.
The article is certainly interesting and important both for
students and for clinical epidemiologists, but some con-
siderations should be pointed out. In terms of recognizing
known cases as such, there are no doubts that the test was
successful, but the results do not give a clear indication as
to how reliably the CIDI can recognize undiagnosed bipo-
lar disorder cases. And, given the straightforward way of
administration of the test compared with other methods,
this is exactly what it will be used for; estimates of disease
prevalence are exactly what we are interested in determin-
ing with the CIDI.
Conclusion
Further research studies are needed on larger "negative"
samples before the field will be persuaded that CIDI really
does what it is supposed to do.
The use of simple self administered tools in two levels
community surveys on Bipolar Spectrum disorders, as the
Mood Disorder Questionnaire [8,9] or the Hypomania
Checklist [10,11], must be seriously considered for meas-
uring the needs for care for Bipolar Spectrum Disorders in
the Community.
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